3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
4
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Colonic Neoplasms
2
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Testicular Germ Cell Tumor
1
Stroke
1
Stomach Neoplasms
1
Renal Insufficiency
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplastic Cells, Circulating
1
Motor Activity
1
Metabolic Syndrome
1
Memory Disorders
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Cirrhosis
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Heart Diseases
1
HPV Positive Oropharyngeal Squamous Cell Carcinoma
1
Interventions
pembrolizumab
25
Gemcitabine
21
Nivolumab
17
Cisplatin
17
atezolizumab
14
Carboplatin
11
avelumab
9
vinflunine
7
Ipilimumab
7
Paclitaxel
6
Docetaxel
5
enfortumab vedotin
4
cabazitaxel
4
Pemetrexed
4
Mitomycin
4
cabozantinib
3
Taxes
3
Rogaratinib
3
Magnetic Resonance Spectroscopy
3
Injections
3
Albumin-Bound Paclitaxel
3
tremelimumab
2
sacituzumab govitecan
2
pemigatinib
2
niraparib
2
lenvatinib
2
bempegaldesleukin
2
apatorsen
2
XRP6258
2
Vitamin D
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Transitional Cell
×
Hematologic Tests
×
Clear all
NCT04566029
2025-12-10
AMI
Centre Hospitalier Universitaire de NÄ«mes
Completed
40 enrolled